CBP80 (N-14): sc-19973



The Power to Question

BACKGROUND

In eukaryotes, the majority of mRNAs have an m(7)G cap, which is added cotranscriptionally and plays a critical role in many aspects of mRNA metabolism. The effect of the cap on translation is mediated by the initiation factor eIF-4F, whereas the effect on pre-mRNA splicing involves a nuclear complex (CBC). CBC consists of two cap binding proteins CBP20 and CBP80, which mediate the stimulatory functions of the cap in pre-mRNA splicing, 3' end formation and U snRNA export. The genes CBC1 and CBC2 encode CBP80 and CBP20, respectively CBP80 comprises three domains, each containing a MIF4G domain. CBP20 has an RNAP fold and associates with the second and third domains of CBP80. CBP also plays a role in nonsense-mediated decay (NMD), which eliminates mRNAs, which prematurely terminate translation. CBP80-bound mRNA undergoes a "pioneer" round of translation before CBP80-CBP20 are replaced by eIF4E, and Upf2 and Upf3 proteins.

REFERENCES

- 1. zaurralde, E., Lewis, J., McGuigan, C., Jankowska, M., Darzynkiewicz, E. and Mattaj, I.W. 1994. A nuclear cap binding protein complex involved in pre-mRNA splicing. Cell 78: 657-668.
- Izaurralde, E., Lewis, J., Gamberi, C., Jarmolowski, A., McGuigan, C. and Mattaj, I.W. 1995. A cap-binding protein complex mediating U snRNA export. Nature 376: 709-712.
- Das, B., Guo, Z., Russo, P., Chartrand, P. and Sherman, F. 2000. The role of nuclear cap binding protein Cbc1p of yeast in mRNA termination and degradation. Mol. Cell. Biol. 20: 2827-2838.
- McKendrick, L., Thompson, E., Ferreira, J., Morley, S.J. and Lewis, J.D. 2001. Interaction of eukaryotic translation initiation factor 4G with the nuclear cap-binding complex provides a link between nuclear and cytoplasmic functions of the m(7) guanosine cap. Mol. Cell. Biol. 21: 3632-3641.
- Mazza, C., Ohno, M., Segref, A., Mattaj, I.W. and Cusack, S. 2001. Crystal structure of the human nuclear cap binding complex. Mol. Cell 8: 383-396.
- 6. Ishigaki, Y., Li, X., Serin, G. and Maquat, L.E. 2001. Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20. Cell 106: 607-617.

CHROMOSOMAL LOCATION

Genetic locus: NCBP1 (human) mapping to 9q22.33.

SOURCE

CBP80 (N-14) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the N-terminus of CBP80 of human origin.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with <0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-19973 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

CBP80 (N-14) is recommended for detection of CBP80 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

CBP80 (N-14) is also recommended for detection of CBP80 in additional species, including canine and bovine.

Suitable for use as control antibody for CBP80 siRNA (h): sc-43669, CBP80 shRNA Plasmid (h): sc-43669-SH and CBP80 shRNA (h) Lentiviral Particles: sc-43669-V.

Molecular Weight of CBP80: 80 kDa.

Positive Controls: Jurkat whole cell lysate: sc-2204.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com